We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Paul F. Abraham
PHOENIX — Watchful waiting was shown to have possible noninferiority to physical therapy as treatment for patients with adhesive capsulitis of the shoulder, based on results of a study presented at the Orthopaedic Research Society Annual Meeting, here.
Furthermore, presenter Paul F. Abraham, BS, said, concerning value-based care, a survey showed patient-incurred costs 12 months after each intervention were greater in the physical therapy (PT) group vs. the watchful waiting group.
He presented results of the interim analysis performed for the 12 patients in the PT arm and the 13 patients in the watchful waiting arm of the study who reached 12-month follow-up. Abraham said patients in both groups were offered corticosteroid injection as needed, and as clinically indicated.
Both groups experienced significantly increased American Shoulder and Elbow Surgeons scores and decreased DASH scores. All patients were also satisfied with their treatments according to the patient-reported outcome measures used, the study showed.
“ASES improvement at 3 months was greater in PT than in watchful waiting, ... but there was no difference at any other timepoint, including at 6 months and 12 months,” Abraham said. “There was no difference in pain improvement between arms throughout the study period either,” he said.
Patients’ average costs were $6,150 for the physical therapy group and $180 for the watchful waiting group, which was a statistically significant difference.
Abraham said, “The clinical take-home of this study is that watchful waiting is equal to PT in the long term in treatment for adhesive capsulitis of the shoulder, but more data are still required to be certain. PT costs are greater than watchful waiting costs, indicating that PT may have a substantially lower value of care than watchful waiting.” – by Susan M. Rapp
Reference:
Abraham PF, et al. Paper 128. Presented at: Orthopaedic Research Society Annual Meeting; Feb. 8-11, 2020; Phoenix.
Disclosure: Abraham reports no relevant financial disclosures.